XORTX Therapeutics (XRTX) Stock Price, News & Analysis

Company Overview

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

Key Stats

• Today's Range: $2.72 to $2.79
• 50-Day Range: $1.73 to $3.03
• 52-Week Range: $1.73 to $7.05
• Volume: 5,735 shs
• Average Volume: 913,558 shs
• Market Capitalization: $3.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

XORTX Therapeutics Stock Analysis - MarketRank™

XORTX Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

XORTX Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

XORTX Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XORTX Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XORTX Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XORTX Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of XORTX Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

XORTX Therapeutics has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in XORTX Therapeutics has recently increased by 128.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XORTX Therapeutics does not currently pay a dividend.

Dividend Growth

XORTX Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for XORTX Therapeutics this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for XRTX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added XORTX Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XORTX Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of XORTX Therapeutics is held by insiders.

Percentage Held by Institutions

0.23% of the stock of XORTX Therapeutics is held by institutions.

XRTX Stock Analysis - Frequently Asked Questions

How have XRTX shares performed this year?

XORTX Therapeutics' stock was trading at $2.81 at the beginning of 2026. Since then, XRTX stock has decreased by 1.2% and is now trading at $2.7750.

How were XORTX Therapeutics' earnings last quarter?

XORTX Therapeutics Inc. (NASDAQ:XRTX) released its quarterly earnings results on Thursday, February, 26th. The technology company reported ($0.45) earnings per share (EPS) for the quarter.

When did XORTX Therapeutics' stock split?

Shares of XORTX Therapeutics reverse split before market open on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, April 1st 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of XORTX Therapeutics?

Shares of XRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of XORTX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XORTX Therapeutics investors own include NVIDIA (NVDA), Aptorum Group (APM), Avalo Therapeutics (AVTX), Coya Therapeutics (COYA), Deswell Industries (DSWL), Dawson Geophysical (DWSN) and EUDA Health (EUDA).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XRTX
• CIK: 1284823
• Web: www.xyratex.com
• Phone: +44-23-92496000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -120.32%
• Return on Assets: -90.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,296,000
• Market Cap: $3.86 million
• Optionable: Not Optionable
• Beta: 0.80